Trial Profile
Clinical pathway for rivaroxaban in patients with cancer-associated thrombosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 09 Feb 2016 New trial record
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.